Free tool
Oncology stocks
We cover 11 companies grouped under the Oncology theme. The median market value in the group is $42.58B. Across the group, the median move over the past trading day is +1.36%. Price change over the past year runs from +1.5% to +88.2% across the middle 80 percent of the group, with a median of +41.3%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
11 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| MRK | Merck & Co., Inc. | $371.70B | Mega cap | +88.17% |
| AZN | AstraZeneca PLC | $263.12B | Mega cap | +7.60% |
| A1ZN34.SA | AstraZeneca PLC | $260.90B | Mega cap | +1.51% |
| BMY | Bristol-Myers Squibb Company | $138.74B | Large cap | +49.31% |
| RVMD | Revolution Medicines, Inc. | $45.35B | Large cap | +492.60% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +21.95% |
| BNTX | BioNTech SE | $28.65B | Large cap | +8.55% |
| INCY | Incyte Corporation | $26.29B | Large cap | +53.04% |
| GMAB | Genmab A/S | $21.42B | Large cap | +41.34% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +49.66% |
| SMMT | Summit Therapeutics Inc. | $10.66B | Large cap | −49.14% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.